IMPORTANCE Adults with acute myeloid leukemia (AML) commonly require support in the intensive care unit (ICU), but risk factors for admission to the ICU and adverse outcomes remain poorly defined.
T he survival of adults with acute myeloid leukemia (AML) has gradually improved during the last 4 decades, largely owing to advances in supportive care and hematopoietic cell transplantation, with some progress made in therapeutic strategies. [1] [2] [3] Although they have contributed to improved survival, contemporary high-intensity therapies for AML bear the risk of complications that require intensive care unit (ICU)-level care. Despite advances in ICU management strategies for hematologic malignant neoplasms, [4] [5] [6] ICU care
remains associated with substantial mortality and long-term sequelae.
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Few studies have examined risk factors for admission to the ICU in patients with AML, with limited data pointing to a role of age, comorbidities, infection, and therapeutic regimens. 10, 11 Conversely, retrospective studies have identified a larger number of possible risk factors for mortality after admission to the ICU in patients with a wider range of hematologic malignancies, including performance status, Acute Physiology and Chronic Health Evaluation score, organ failure, need for mechanical ventilation, and use of vasopressors. 4, 9, 10, [12] [13] [14] [15] However, most of these studies were small, single-institution investigations, limiting generalizability given variability across ICUs. 16 Furthermore, few studies have focused specifically on patients with AML, although some evidence indicates that outcomes in such patients are particularly poor. 13, 14 Finally, while of great interest from a medical and economic perspective, to our knowledge, the effects of ICU care on use of health care resources, length of stay (LOS), and costs have not been evaluated. Understanding relevant risk factors for admission to the ICU and short-term mortality, the primary goal of this study, is an essential step in identifying patients with AML at high risk for adverse events. This understanding would allow for the development of preemptive strategies aimed at optimizing treatment outcomes and reducing the economic consequences of AML therapy.
Methods

Data Source
The University HealthSystem Consortium constitutes a collaboration between academic and affiliated health institutions for the purposes of research and clinical practice analysis. 17 Currently, the University HealthSystem Consortium includes 117 academic centers with 338 affiliated hospitals throughout the United States, representing 43 states. The consortium established a longitudinal hospitalization database comprising a set of prespecified clinical variables (not including laboratory, radiologic, or pathologic data or cause of death) prospectively abstracted by certified coders from discharge summaries, and cost charges generated by consortium institutions. Data collection is closely monitored and strictly quality controlled to ensure completeness of data. For this analysis, no direct patient or institutional identifiers were provided to the investigators. Institutional review board waiver was granted by Duke University, Durham, North Carolina, where the original analysis was conducted, and completed at the Fred Hutchinson Cancer Research Center, Seattle, Washington. A waiver was granted on the basis that no patient identifiers were used. No informed consent was required.
Patient Population
The study population consisted of all adults 18 years or older with newly diagnosed, relapsed, or refractory AML who were hospitalized for any cause between January 
Results
Patient Characteristics
A total of 126 076 hospitalizations were reported for 49 530 patients with AML at 229 hospitals during the study period, with 26 102 patients (52.7%) admitted more than once. We excluded 6281 patients with a history of hematopoietic cell transplantation (5996 allogeneic and 285 autologous), leaving 43 249 for the final analysis. 
Length of Stay and Cost
The mean (median) LOS for patients who were not admitted to the ICU was 15.3 (8.0) days, compared with 22.4 (18.0) days for patients requiring ICU admission. On univariate analysis, other factors associated with prolonged hospitalization included age, geographical region, hospital volume, infection, and comorbid conditions ( Table 4) . 
Discussion
Treatment-related mortality in patients with AML has decreased during the past 2 decades. 2, 20 Consistent with this fact, we found a decrease in mortality during the study period in our whole patient cohort. However, this decrease was almost entirely driven by reduced early mortality in patients not requiring ICU care, whereas ICU admission rates have only slightly decreased and ICU stays remained associated with persistently high mortality and rising costs during the past decade. Although models are available to estimate the risk of treatment-related mortality after initial intensive chemotherapy for newly diagnosed AML 21 or for patients undergoing hematopoietic cell transplantation, 22 to our knowledge, no tools exist to reliably recognize patients at risk for ICU admission and Abbreviation: ICU, intensive care unit. a N = 11 277 patients analyzed.
b Adjusted for clustering of the observations from the same hospital.
subsequent short-term mortality. Here, we identify demographic variables, systemic factors, and potentially modifiable medical characteristics (eg, comorbidities and infections) associated with ICU admission, in-hospital mortality, and resource use in patients with AML. These findings could spawn the development of prediction models for ICU use and outcome, which might provide a tool for risk stratification, facilitate patient counseling, and could ultimately lead to new primary prevention and intervention strategies aimed at decreasing morbidity and mortality. Through targeting of modifiable risk factors, such strategies may be useful for improving patient outcomes.
Intensive care unit use and cost have risen in the United States since the 1990s, and critical care services now represent a higher proportion than ever before of the gross domestic product. 23 Consistent with this trend, cost estimates in our analysis were more than double for patients with AML requiring ICU admission compared with those who did not, and increased over time despite stable mortality rates, stable total hospital LOS, and decreased ICU LOS. The specific reasons for this disproportionate rise in cost remain unknown, as detailed epidemiologic data encompassing the hospital care and resource use of patients with AML are lacking, 24 but are likely interrelated with the increase in health care costs in general and in cancer care and ICU costs in particular. 25 These costs are fueled by increasingly expensive therapies as well as expansion in the extent of care offered and the use and availability of technology in the oncology and critical care settings. 26 An important step in addressing this rise in costs of cancer care includes the identification of contributing, modifiable factors, as revealed in our study. This knowledge provides the basis for future investigations on how these risk factors could be mitigated to reduce ICU use in patients with AML. Another factor contributing to high costs are readmissions, 27 which are common in patients with AML for both disease-and treatment-related complications. Notably, 23 428 patients (47.3%) in our database had only a single admission. In analyzing this subgroup, we found several potential contributing factors, including death on this first admission (6649 [13.4%]) as well as a higher rate of single admissions in the final year of the study period. Furthermore, these patients were more likely to be admitted to hospitals with lower volume, and thus possibly transferred to tertiary care centers not in the consortium for further care, and were older, and therefore potentially less likely to be treated and readmitted for complications. An upcoming study will examine risk factors for readmissions in patients with AML. Evidence has demonstrated that hospital volume can affect mortality of patients undergoing surgical or medical cancer treatments. 28 For patients with AML, previous studies indicated that mortality rates while undergoing chemotherapy are lower in high-volume vs low-volume centers despite similar mean LOS and cost. 29 In this study, we found that hospital volume was not independently associated with mortality in patients with AML requiring ICU care, but that mean LOS and costs were significantly higher at high-volume hospitals. Referral bias of sicker patients to hospitals with higher volumes, and increased availability, and therefore use of, resources in hospitals with higher volumes may partly explain this observation, a notion supported by data indicating that ICU bed supply increases ICU bed use and health care spending, even after controlling for severity of illness. 30 This difference may account for greater spending on critical care services in the United States compared with other countries 30 and offers a rational target for intervention. The use of a preexisting database offers several advantages, including the economy of data on a large scale and a large sample size, aspects uncommon to studies of patients with AML. In addition, as many recommendations for management of AML are based on findings from selected study patients that may not be applicable to the general population with AML, 31 ,32 the use of real-world patient data may provide 
Limitations
First and foremost, the University HealthSystem Consortium database relies on administrative coding and captures only hospital-based care. However, these limitations are unlikely to significantly affect our findings, as coding for AML and comorbidities has been validated in prior reports and found to be accurate, 33, 34 and most resource-intense care management of patients with AML remains hospital-based. In addition, depending on the coder, some patients in remission but receiving consolidation therapy for their disease likely were included as having active AML; inclusion of these patients, who may be considered less sick, may have lowered our estimates of poor outcomes and resource use. Furthermore, the variables available for analysis were predetermined and did not include data on disease characteristics (eg, cytogenetic profile), treatment phase (induction vs consolidation), response to therapy, reason for hospital and ICU admission, use of prophylactic antimicrobials, and cause of death. To address some of these limitations, we performed exploratory analyses investigating the effect of some of these factors by identifying patients with relapsed disease and those with a concurrent diagnosis of myelodysplastic syndrome, potentially a surrogate for AML with an antecedent hematologic disorder. Although patients with relapsed AML had a slightly lower risk of ICU admission than other patients, which remained significant in multivariable analysis (791 of 3383 [23.4%] vs 10 486 of 39 866 [26.3%] ; odds ratio, 0.73; 95% CI, 0.67-0.80; P < .001), relapsed disease was not independently associated with mortality in multivariable analysis. Furthermore, concomitant diagnosis of myelodysplastic syndrome did not independently affect the risk of ICU admission or mortality in multivariable analysis. Another limitation is that the random selection of 1 hospitalization for patients admitted more than once during the study period may have led to an underestimate of true resource use, as patients with AML are often readmitted in short time spans for treatment-related complications, such as neutropenic fever, infections, or adverse effects on organs. Finally, the criteria for ICU admission vary among institutions, introducing heterogeneity into our study cohort. For example, admission of less sick patients to certain ICUs may affect mortality and estimates of resource use but would be expected to yield smaller, rather than larger, differences between patients requiring and not requiring ICU care.
Conclusions
Our findings demonstrate that ICU care remains common in patients with AML and is associated with substantial mortality and an increasing demand on health care resources over time. The identification of several factors that are significantly associated with ICU admission, mortality, and cost provide the basis for the development of tools for personalized, informed decisions in the management of AML that can assist in optimizing resource use for patients with AML and improving treatment outcomes.
